Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL)

Victory Capital Management Inc. purchased a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 44,880 shares of the company’s stock, valued at approximately $543,000. Victory Capital Management Inc. owned 0.07% of Replimune Group as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Erste Asset Management GmbH purchased a new position in shares of Replimune Group during the 3rd quarter valued at about $133,000. BNP Paribas Financial Markets lifted its position in shares of Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after buying an additional 6,748 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Replimune Group in the 3rd quarter worth approximately $222,000. Finally, Intech Investment Management LLC purchased a new position in Replimune Group in the 3rd quarter worth approximately $252,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on REPL shares. JPMorgan Chase & Co. boosted their price target on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Performance

NASDAQ REPL opened at $10.82 on Friday. The company has a market cap of $833.30 million, a P/E ratio of -3.52 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The business’s 50 day moving average price is $12.66 and its 200-day moving average price is $12.14. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Sell-side analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.